The Future of Longevity
A panel discussion series with leading experts in rejuvenation science and biotechnology.
Next panel discussion: July 14th, 2021 @ 1:00PM (EST)
Wednesday, July 14th, 2021 @ 1PM (EST) On Clubhouse.
George Church (Harvard Medical School)
Nir Barzilai (Albert Einstein College of Medicine)
Jim Mellon (Juvenescence)
Jay Olshansky (University of Illinois at Chicago)
Kristen Fortney (BioAge Labs)
Alejandro Ocampo (University of Lausanne)
Wednesday, June 15th, 2021 @ 1PM (EST) On Clubhouse.
Aubrey de Grey: The chief scientist officer and co-founder of the SENS research foundation. Aubrey is a biomedical gerontologist, author of ‘Ending Aging‘ and one of the longest proponents to study the field of longevity.
David Sinclair: Is the Professor of genetics and co-director of the Paul F. Glenn centre for the biology of aging at Harvard medical school. David is also the author of Lifespan, and his research focuses on understanding and slowing the pace of aging through a variety of approaches.
Jean Hebert: Is an Associate Professor in the department of genetics at the Albert Einstein college of medicine, and author Replacing Aging. Jean spends his time devising methods of cell replacement for the adult neocortex, where its cells are lost due to damage or age-related to degeneration.
Joao Pedro de Magalhaes: Is a microbiologist and Professor at the University of Liverpool. The goal of Joao’s work is to understand the genetic cellular and molecular mechanisms of aging across all organisms.
Greg Fahy: Is the vice president and chief scientist officers of 21st century medicine, and the founder of Intervene Immune. Greg is also a cryobiologist, biogerontologist, and businessman based in California. His research focuses on organ cryopreservation by vitrification.
Detailed transcript of this talk with a breakdown of the questions is available here:
Longevity Panel – The Scientists Working to Reverse Aging | Part 1 | Panelist QuestionsLongevity Panel – The Scientists working on Reversing Aging | Part 2 | Audience Questions
Cynthia Kenyon discovers a mutation in the daf-2 gene that doubles the lifespan of C. Elegans. Her work along with that of Thomas Johnson sparked intensive study into the molecular basis of aging.
Over 100 + longevity biotech companies, 47+ clinical trials, dozens of venture capital firms, and 300+ academic labs converging to understand and treat the root cause of major disease: Aging.
Laura Minquini is a branding specialist. She brought to market the first fashion-focused tech accessories brand, achieving world wide distribution, millions of dollars in sales, and has collaborated with companies like Louis Vuitton, Apple, colette, and Pantone. She believes Longevity can be the next big consumer category.
Avi is a biomedical scientist and entrepreneur based in Oxford. He advises and funds startups in the health and longevity space in North America, Europe, and India. Additionally, he collaborates with government agencies on policies that facilitate the longevity infrastructure.
Currently, Avi is an advisor to The Happiness Foundation, Memesys Culture Lab, and Gowing Life, Ltd. Among Avi's previous positions, he was the CTO of BioViva, and a post-doctoral research fellow at the University of Oxford's CASMI. During his PhD, Avi led the Oxford University Scientific Society, and he was president of The Biogerontology Research Foundation.
Program Director at On Deck Longevity Biotech
Founder, Longevity Marketcap
Nathan Cheng is the Program Director of the On Deck Longevity Biotech Fellowship and founder of Longevity Market cap, the most widely read longevity investing newsletter in the world.
He is also an investor, founder of Healthspan Capital and Longevity List.
"I believe that aging is a disease. I believe it is treatable. I believe we can treat it within our lifetimes."
David A. Sinclair, Professor of genetics at Harvard Medical School
Come join us in a live panel discussion and Q&A on longevity science and biotechnology every month.
We received your email address. We will remind you of any upcoming panel discussions.